I encourage people to read (or re-read) this Ars Technica article, especially the second to last paragraph (the one that begins: "To get around the sustainabili

I encourage people to read (or re-read) this Ars Technica article, especially the second to last paragraph (the one that begins: "To get around the sustainability issue overall[…]") and put your prejudices aside when you do so. There is nothing "broken" about the pharmaceutical industry being described here. The Goldman guy's opinion is that the industry should focus on treating the conditions that affect the greatest number of people, double down on innovation, and turn their focus towards improving the lives of the elderly—which we're all counting on being, once the promise of gene therapy cures the maladies younger and middle aged people suffer from. Oh, the horror!